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A Mendelian randomization study
of telomere length and blood‑cell
traits
Charleen D. Adams1* & Brian B. Boutwell2,3
Whether telomere attrition reducing proliferative reserve in blood-cell progenitors is causal has
important public-health implications. Mendelian randomization (MR) is an analytic technique using
germline genetic variants as instrumental variables. If certain assumptions are met, estimates from
MR should be free from most environmental sources of confounding and reverse causation. Here,
two-sample MR is performed to test whether longer telomeres cause changes to hematological traits.
Summary statistics for genetic variants strongly associated with telomere length were extracted
from a genome-wide association (GWA) study for telomere length in individuals of European ancestry
(n = 9190) and from GWA studies of blood-cell traits, also in those of European ancestry (n ~ 173,000
participants). A standard deviation increase in genetically influenced telomere length increased red
blood cell and white blood cell counts, decreased mean corpuscular hemoglobinand mean cell volume,
and had no observable impact on mean corpuscular hemoglobin concentration, red cell distribution
width, hematocrit, or hemoglobin. Sensitivity tests for pleiotropic distortion were mostly inconsistent
with glaring violations to the MR assumptions. Similar to germline mutations in telomere biology
genes leading to bone-marrow failure, these data provide evidence that genetically influenced
common variation in telomere length impacts hematologic traits in the population.
Abbreviations
MR	Mendelian randomization
RBC	Red blood cell
WBC	White blood cell
Ret	Reticulocyte
MCH	Mean corpuscular hemoglobin
MCV	Mean cell (corpuscular) volume
MCHC	Mean corpuscular hemoglobin concentration
RDW	Red blood cell distribution width
Hct	Hematocrit
Hgb	Hemoglobin
GWA	Genome-wide association
HSC	Hematopoietic stem cell
BMF	Bone marrow failure
IBMFS	Inherited bone marrow failure syndromes
In humans, telomeres, DNA repeats and protein structures that “cap” and stabilize the ends of chromosomes,
progressively shorten across the l ifespan1. As a result, telomere length has generally been viewed as a biomarker
of aging2. Natural variation for telomere length exists, moreover, with a portion of the variance resulting from
genetic variation3 (e.g., heritability estimates ranging from 36 to 82%4). While heritable influences likely capture a variety of contributing mechanisms, there is reason to suspect that they heavily reflect both the activity
of the ribonucleoprotein enzyme telomerase, which acts to maintain telomere length, as well as the effects of
environmental (e.g. exogenous oxidative or inflammatory) stressors that can accelerate telomere s hortening5,6.
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Blood, like telomere length, affects and is affected by its environment: what happens in and to blood impacts
physiological processes throughout the body, and blood cells also carry the signatures of environmental stressors
(e.g., smoking- and alcohol-related DNA methylation changes in leukocytes7,8). Telomere length can be thought
of as an environmentally pliant and endogenous exposure for cells. A DNA damage response may be elicited and
cellular senescence ensue if telomeres become critically short9. Telomere length in white blood cells (WBCs) may
approximately reflect telomerase activity in hematopoietic stem cells (HSCs)10. This becomes broadly relevant,
to be sure, as telomerase activity appears to be inadequate at preventing telomere erosion11. As hypothesized by
Mazidi et al.12, telomere attrition may be a marker for reduced proliferative reserve in hematopoietic progenitor
cells.
An established relationship exists between rare telomerase mutations and bone marrow failure syndromes13.
As Savage and Bertuch4 discuss in their review, telomere biology disorders are, indeed, defined by very short telomeres. Affected persons are highly susceptible to cancer, pulmonary fibrosis, and bone marrow failure (BMF)4.
BMF can be the first sign of a telomere biology disorder, in fact. Aplastic anemia, a BMF condition which can
be acquired or inherited and which results from damage to HSCs14, leads to hallmark cytopenia: low circulating
RBCs, WBCs, and platelets. Fascinatingly, telomere length can be shorter than normal in those with acquired
aplastic anemia, but not as short as for those with canonical telomere biology d
 isorders4. Likewise, lower red
blood cell (RBC) counts, larger RBC size, and lower platelet counts have been observed in subjects with germline
telomerase reverse transcriptase (TERT) mutations compared with family c ontrols15.
At least 70% of patients with dyskeratosis congenita, which has the most severe phenotype of the telomere
biology disorders4, carry germline mutations in telomere maintenance genes13. Moreover, similar to telomere
length in those with acquired anemia sometimes being shorter than in non-affected individuals—but not as
short as in those with established telomere biology disorders4—telomere length in those with inherited bone
marrow failure syndromes (IBMFSs) other than dyskeratosis congenita have been documented to be shorter than
in unaffected individuals. But they are not as short as in those dyskeratosis congenita13. This implies a dose-like
relationship between the heritable component of telomere length and disease severity, which is especially notable
with BMF in dyskeratosis congenita, associated with accelerated telomere s hortening16.
The heritable component to telomere length may not necessarily be limited to mutations directly in telomere
biology, however. For instance, there is a lack of evidence for mutations in telomere biology genes in patients
with Fanconi anemia (an IBMFS), for which BMF is the most likely adverse outcome during childhood (relative
to solid tumors being more likely in adulthood), and in which shorter telomeres have been documented17. With
Fanconi anemia, Pang and Andreassen and Sarkar and Liu postulate that telomere defects occur secondary to
endogenous oxidative damage18,19.
By extension, these hints of dose-like relationships raise the possibility that common variation (like a small
dose in susceptibility from a single nucleotide polymorphism [SNP] rather than a large dose from a rare mutation) in telomere maintenance genes might confer an effect on blood-cell traits, though in a blunted, ostensibly
subclinical, manner in comparison to the mutations causing IBMFS. And, while subclinical, these changes could
still be relevant to the pathophysiology of common diseases of aging in the population.
Telomere length is, indeed, hypothesized to be associated with hematologic traits in the general population.
For instance, in an observational study of 3156 subjects, Kozlitina et al. found that shorter telomere lengths were
associated with lower RBC counts, larger mean RBC size, increased red blood cell distribution width (RDW),
higher hemoglobin levels, and lower platelet c ounts6.
The Kozlitina study was small, however, and observational studies are prone to potential confounding and
reverse causation. Indeed, a few other small studies have examined telomere length and blood-cell traits with
results that are discrepant between the studies12. To wit, the results for the study by Mazidi et al.12 partly conflict
with those by Kozlitina et al.6. They observed a negative relationship between telomere length and monocyte
count, for i nstance12. Due to this, it is unclear whether a causal relationship exists between telomere length and
blood-cell traits in the general population.
Using Mendelian randomization (MR), Haycock et al. observed that longer telomeres (in leukocytes)
increased the risk for various cancer outcomes, but decreased the risk for coronary heart disease20. Since variation in blood-cell subtype is associated with a wide variety of systemic d
 iseases21 and since blood cells play an
essential role in key physiological processes (e.g., oxygen transport, hemostasis, and innate and acquired immune
responses)22–24, the activity of blood-cell traits may mediate or exacerbate some of the effects of telomere length
on various disease outcomes and/or reflect changes resulting from various diseases. Teasing out the underlying
causal relationships has important clinical and public-health implications.
To that aim, MR is an analytic, quasi-experimental technique that uses germline genetic variants as instrumental variables. If certain assumptions are met, estimates from MR should be free from most social and environmental sources of confounding and reverse causation (see Methods)25, and can, therefore, help sort out
the nature of complexly woven traits. Here, MR is used to examine the effect of genetically influenced longer
telomeres on nine blood-cell traits.

Results

Red blood cell (RBC) and white blood cell (WBC) counts. Genetically increased telomere length

was associated with higher inverse-variance weighted (IVW) estimates (95% CIs) for 2 of 9 blood-cell traits
(P < 0.006): RBC count 0.09 (0.04, 0.14) and WBC count 0.06 (0.02, 0.11). The sensitivity estimators aligned in
the direction and magnitudes of their effects, and the MR-Egger intercept tests (Supplementary Tables 10–11)
indicated no evidence for directional pleiotropy. The I2 statistic for the MR-Egger test pointed to some potential
regression dilution, though the values were close to 90%, indicating that the MR-Egger tests suffered at most
from up to 14% potential dilution from this bias. The Simulation Extraction (SIMEX) correction of the MR-
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Egger estimates revealed that the corrected MR-Egger intercepts were different than zero (an MR-Egger intercept test consistent with zero indicates a lack of evidence for pleiotropy in the IVW estimate). While this could
imply distortion from pleiotropy in the IVW estimate (Supplementary Tables 10–11), the SIMEX correction may
be overly conservative, since the potential dilution was small.

Reticulocyte count.

There was intermediate evidence that genetically increased telomere length was associated with higher reticulocyte count (P < 0.05): IVW estimate 0.04 (95% CI 0.00, 0.08). The sensitivity estimators aligned in the direction and magnitudes of their effects, except, crucially, for the MR-Egger estimate, for
which the direction of effect was reversed. The MR-Egger intercept test (Supplementary Table 12) indicated no
evidence for directional pleiotropy. The I2 statistic for the MR-Egger test pointed to some potential regression
dilution, indicating that the MR-Egger test suffered from up to 13% potential dilution from this bias (potential
bias of < 10% is typically considered acceptable). The SIMEX correction of the MR-Egger estimate made no difference in the interpretation of the findings (the MR-Egger intercept remained null). Overall, however, due to
the discordance between the IVW and the MR-Egger estimates, the finding could be influenced by violations to
the MR assumption against horizontal pleiotropy.

Mean corpuscular hemoglobin (MCH) and mean corpuscular (cell) volume (MCV). Genetically

increased telomere length was associated at the Bonferroni threshold with lower IVW estimates [95% CIs] for
2 of the 9 blood-cell traits (P < 0.006): MCH (− 0.12 [− 0.18, − 0.07]) and MCV (− 0.13 [− 0.18, − 0.08]). The
sensitivity estimators aligned in their direction of effects and mostly in their magnitudes. The MR-Egger intercept tests (Supplementary Tables 13–14) indicated no evidence for directional pleiotropy. The I2 statistic for the
MR-Egger test to minimal (up to 11%) potential dilution. SIMEX correction of the MR-Egger estimates indicated that the corrected MR-Egger intercepts remained consistent with zero after correction (Supplementary
Tables 13–14).

Mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), hem‑
atocrit (Hct), and hemoglobin (Hgb). Genetically increased telomere length was not associated with

4 of the 9 blood-cell traits: MCHC (− 0.02 [− 0.06, 0.02]), RDW (0.02 [− 0.02, 0.06]), Hct (0.03 [− 0.02, 0.08]),
RDW (0.04 [0.00, 0.08]). The sensitivity estimators mostly aligned in their magnitudes of effects, but for the
MCHC estimate, several of the estimators were reversed in direction from that of the IVW. The MR-Egger intercept tests (Supplementary Tables 15–18) indicated no evidence for directional pleiotropy. The I2 statistic for the
MR-Egger test indicated up to ~ 15% potential dilution from this bias. The SIMEX correction of the MR-Egger
estimates indicated that the corrected MR-Egger intercepts remained consistent with zero after correction (Supplementary Tables 15–18): no change in interpretation.

Discussion
Summary.

The MR analysis of telomere length on blood-cell traits support the notion that telomere length
influences some of the traits in a causal manner. Longer telomeres increased RBC and WBC counts and decreased
the measures of MCH and MCV, but had no observable impact on MCHC, RDW, hematocrit, or hemoglobin.
The sensitivity tests for potential pleiotropic distortion were mostly inconsistent with glaring violations to the
MR assumptions. Supposing the MR assumptions have not been violated, which can never fully be tested (a
limitation of this study and of all MR studies generally), these data support the growing evidence that longer
telomeres impact blood cells.

Relevance for disease and aging. As for what this means for the clinic and for the population at large,
De Meyer et al. suggested that there may be an age-dependent effect of telomere length on blood-cell traits. In
their population-based study, they observed a positive correlation between telomere length and RBC count that
was, importantly, stronger for those older than 45 years of a ge26. This suggests that the impact of telomere length
on RBCs may be negligible in middle age but have important clinical consequences in the elderly, related to the
anemia of chronic d
 isease26. Thus, longer telomeres increasing RBC count may be beneficial and protective,
especially during the later years of life.
The protective effect may be dampened some, however, by the fact that no relation was observed for longer
telomere length and hemoglobin concentration in the present study. Nonetheless, a pattern of longer telomeres
increasing RBCs and WBCs but not hemoglobin concentration comports with those of an observational study
among Polish individuals over 6510. For men specifically, Gutmajster et al.10 detected weak positive correlations
between telomere length and RBCs and WBCs and no signal for hemoglobin. The present data dovetails with
theirs, supporting the hypothesis that telomere shortening hinders hematopoiesis capacity.
Moreover, in the Kozlitina et al. study, an inverse association was observed between telomere length and
MCV6. Our findings for MCV comport with Kozlitina et al.’s and support the idea that telomere shortening is a
mechanism for the macrocytosis of aging.
Haycock et al. observed that increased telomere length increased the odds for lung adenocarcinoma (odds
ratio and 95% CI 3.19 [2.40–4.22]) and other c ancers20, and Sprague et al. documented that higher WBC count
increased the hazard estimates for lung cancer27. Thus, it is conceivable that there is a pathway from longer
telomeres to lung cancer through an impact on increasing WBC count, a marker of i nflammation28. A body of
evidence suggests that chronic low-grade inflammation is involved in the pathogenesis of various cancers, where
cancer causes inflammatory, microenvironmental, and immune changes to the host29–33. Therefore, since longer
telomeres appear to contribute to the initiation of some cancers and these early carcinogenic changes potentially
promote increased WBC count, increased WBC count might reflect undiagnosed cancer. If longer telomeres
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increase WBC counts and contribute to cancer initiation, and, in turn, the subsequent (possibly subclinical)
tumor increases WBC, this would be an example of bidirectional causality.

Bidirectional causality versus reversion causation. Bidirectional causality is different conceptually
from reverse causation, and because it could be relevant to our findings, it is useful to draw out the distinctions.
With a true bidirectional relationship, causation occurs in both directions, as the name suggests. For example,
there is a bidirectionally causal relationship between fluid intelligence and years of schooling. Higher intelligence
causes people to stay in school longer, and staying in school longer feeds back on and increases intelligence34.
This bidirectionality is different than what is typically meant by “reverse causation”. In non-experimental studies,
where temporality cannot be confidently sussed out, the direction of the correlation is challenging, or impossible, to infer. When the actual underlying causal direction is opposite from what investigator’s hypothesize, this
is an example of reverse causation. MR studies are specifically designed to subvert reverse causation. This is so,
owing to the fact that genotype assignment at conception temporarily precedes other physiological parameters
of interest. This robustness to reverse causality is one of the overarching strengths of MR and why MR is an
essential tool for population-based medical research. Relative to observational designs, the risk for reverse causation is greatly reduced.
However, it is not impossible, as VanderWeele et al.35 point out. Scenarios can arise in which an exposure and
outcome of interest are each partitioned into several time points. For instance, imagine an outcome at its “time 1”
that affects an exposure at the exposure’s “time 2”. This can approximate reverse causation in MR since the genetic
variant proxying for the exposure at “time 1” is now not independent of the final outcome at “time 2”, conditional
on both exposure time points and potential confounders35. Fortunately, this should be the exception rather than
the rule. While possible that one exists, absent knowledge of an empirical, a prior reason to think that telomeres
impact blood-traits at multiple time points in such a way that blood-cell traits influence telomeres at “time 2”, a
more parsimonious explanation is that the relationships between telomeres and blood cells are bidirectional, if
indeed blood-cell traits impact telomeres. Blood-cell traits might very well do so, given that blood-cell traits are
involved in oxidative and inflammatory processes.
Whether blood-cell traits cause changes in telomere length is an important avenue for future MR research.
In order to examine the influence of blood-cell traits on telomere length with two-sample MR (the design used
here), the full summary statistics for a large telomere-length GWA study would be needed. While the findings
deemed “statistically significant” for the telomere-length GWA study used here to instrument telomere length are
public, the full summary statistics, including the non-top findings, are not available. For now, this precludes MR
investigations of bidirectional relationships between longer telomeres and blood-cell traits using the Mangino
et al. GWA data as the outcome data source. Additionally, and more importantly, a telomere-length GWA study
that is substantially larger than Mangino et al.’s3, which included ~ 9,200 participants, would be needed to best
capitalize on the power of large samples to detect effects. Another GWA study of telomere length does exist: Codd
et al. contains ~ 38,000 individuals36. This is the more-apt GWA dataset to use when treating telomere length as
the outcome, (or even better, an even larger one). At present the full summary statistics are not publicly available.
To further emphasize this issue, the Astle et al.21 GWA studies for blood-cell traits we used here were performed
on ~ 173,000 individuals. This makes the Astle et al.21 GWA studies strong resources for studying blood-cell traits
as outcome variables in two-sample MR.
Returning briefly to the example of the bidirectional relationship between intelligence and education years,
a bidirectional MR analysis of these traits was able to determine the prevailing direction of effect. Specifically,
and intriguingly, while intelligence influences how long someone stays in school, the magnitude of the impact
of staying in school on intelligence is much larger34. This has important implications for interventional policies.
Similarly, determining the prevailing direction of effect, if a bidirectional relationship between telomere length
and blood-cell traits exists, has the potential to inform and refine strategies for disease prevention.
The issue of bidirectionality gets thicker when turning attention to coronary heart disease (CHD). A potentially puzzling relationship exists between longer telomeres, more WBCs, and CHD. Haycock et al.’s. MR study
and also evidence from clinical studies suggest a protective effect of longer telomeres against CHD20,37. But a
vast body of clinical and epidemiologic literature suggests that higher WBC counts contribute to CHD’s pathogenesis. This makes it challenging to explain the impact of telomeres increasing WBCs, as they relate to CHD.
The proposed mechanisms for the deleterious effects of WBCs on CHD, as entrenched and entangled as they are
with likely bidirectional causality, are hard to ignore. For instance, previously suggested “mechanistic” explanations include the fact that higher WBC counts are a biomarker of atherosclerotic stress; a secondary signal from
inflammation due to tobacco smoking; a contributor to microvascular injury; and a reflection of complex and
systemic inflammatory responses, involving cytokines, cell-adhesion molecules, T-lymphocytes, and C-reactive
protein38, etc. But if the observational evidence is causal, then this suggests that longer telomeres and more
WBCs have, perhaps, independent and opposing direct effects on CHD, even if longer telomeres increase WBC
count, as suggested by the data here. Whether there are independent, direct effects of more WBCs and longer
telomeres on CHD is a question that could be investigated with multivariable MR – once full summary statistics
are available for telomere length (again from a large GWA study).
Lastly, chronic inflammation, independent of shorter telomere length, can lead to premature senescence. This
may enhance the effects of shorter telomeres, which also cause senescence when short enough37,39. Moreover,
since (a) longer telomeres in WBCs likely reflect longer telomeres in hematopoietic stem cells (HSCs) and (b)
epithelial progenitor cells (EPCs) originate from HSCs and are involved in the repair mechanisms for vascular
atherosclerosis37, shortened telomeres in WBCs may reflect compromised capacity to repair injured vasculature.
Therefore, longer telomeres may be protective against CHD by not interfering with the generation of EPCs and
their involvement in vasculature repair. To the extent that more WBCs reflect EPC health and integrity, more
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Figure 1.  Illustration of two-sample MR using the test of the causal effect of telomere length on red blood cell
(RBC) counts as an example. Estimates of the SNP-telomere length associations (βZX ) are calculated in sample
1 (from a previous GWA study of telomere length). The association between these same SNPs and RBC counts
are then estimated in sample 2 (βZY ) (from a GWA study of RBC counts). The estimates from the instrumental
SNPs are combined into Wald ratios (βXY = βZY /βZX ). The βXY ratio estimates are meta-analyzed using
the inverse-variance weighted (IVW) analysis (βIVW) method, which produces an overall causal estimate of
telomere length on RBC counts. Sensitivity estimators are used to judge whether the IVW causal estimate is
plausible (more below).

WBCs may be a protective marker. To the extent that more WBCs reflect increased inflammation, more WBCs
appear to contribute to CHD.
In conclusion, similar to how germline mutations in telomere biology genes can lead to BMF, the present
findings from two-sample MR provide evidence that genetically influenced common variation in telomere length
impacts hematologic traits in the population. Future MR studies should explore whether blood-cell traits also
impact telomere length, as similar to endogenous oxidative damage in Fanconi anemia possibly influencing
telomere length, oxidative damage related to immune cell responses might influence telomeres in the population.

Methods

Conceptual approach. Non-experimental studies are prone to confounding and reverse causation. MR

gets around these issues, using an instrumental-variables framework, by exploiting the random assortment of
alleles, genotype assignment at conception, and pleiotropy (genes influencing more than one trait)25,40,41. Using
genetic variants instrumentally avoids most environmental sources of confounding, and genotype assignment
at conception avoids most sources of reverse causation, since genotypes temporarily precede the observational
variables of interest.
Two-sample MR is a version of the procedure that uses summary statistics from two genome-wide association
(GWA) studies42–47. Typically, with two-sample MR, the IVW method is the standard approach (Fig. 1 contains
an example).

Mendelian randomization assumptions. MR relies on the validity of three assumptions48. In the con-

text of the present analysis, these assumptions are as follows: (1) the SNPs acting as the instrumental variables
for telomere length are strongly associated with telomere length; (2) the telomere-length-associated SNPs are
independent of confounders of telomere length and the outcomes of interest; and (3) the telomere length SNPs
are associated with the outcomes of interest only through telomere length (no horizontal pleiotropy; the SNPs
are not associated with the outcomes independent of telomere length44,48).

Instrument construction. For the telomere length instruments (βZX in Fig. 1), SNPs associated at genomewide significance (P < 5 × 10–8) with a standard deviation (SD) in telomere length, whose summary statistics
(effect estimates and standard errors) were concatenated and reported by Haycock et al.20 were selected. The
original telomere-length GWA study was a meta-analysis performed across six cohorts on 9190 individuals
(men and women aged 18–95) of European ancestry3. (Detailed descriptions of the six cohorts are available
elsewhere49–54, but for ease of reference, Mangino et al.3 included the following six cohorts in their meta-analysis
of telomere length: the Framingham Heart Study, Family Heart Study, Cardiovascular Health Study, Bogalusa
Heart Study, HyperGEN, and TwinsUK). Mangino et al.3 adjusted for age, a ge2 sex, and smoking history and
checked for non-European ancestry with principal components analysis. From the meta-analysis, sixteen SNPs
were available for this MR analysis (Supplementary Table 19). Those that were independent (not in linkage
disequilibrium, LD, with an r2 < 0.001, at a clumping distance of 10,000 kilobases with reference to the 1000
Genomes Project (https://www.internationalgenome.org/) were kept and those that did not fit this criteria were
dropped. The corresponding effect estimates and standard errors for the retained SNPs were then obtained from
the blood-trait GWA studies (βZY in Fig. 1). The blood-trait GWA studies were performed by Astle et al.21 on
a population of ~ 173,000 individuals of European ancestry, largely from the UK (a meta-analysis of the UK
Biobank and Interval studies). They adjusted for principal components and study center and excluded those with
blood cancers or major blood disorders.
When a SNP was not available in the blood trait GWA studies, a “proxy” SNP in LD with the SNP at r 2 ≥ 0.80
(assessed using 1000 Genomes Project) was chosen. If the “proxy” SNP was not available, the SNP was removed
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Test

Strength

IVW analysis

Outcome (N)
No. SNPs

R2

F

RBC (172,952)

0.01

13

β (95% CI)
0.09 (0.04, 0.14)

Weighted median
P
2.4E−04*

β (95% CI)
0.09 (0.03, 0.15)

P
1.9E−03

Weighted mode

MR-Egger

β (95% CI)

P

β (95% CI)
I2 statistic

P

3.2E−02

0.11 (0.00, 0.23)

1.1E−01

0.09 (0.03, 0.16)

I2 = 86

SNPs = 7
WBC (172,435)

0.01

15

0.06 (0.02, 0.11)

4.2E−03*

0.07 (0.02, 0.12)

7.5E−03

0.07 (0.02, 0.12)

7.5E−02

Ret. (170,641)

0.02

17

0.04 (0.00, 0.08)

3.3E−02

0.04 (− 0.01, 0.09)

1.2E−01

0.03 (− 0.02, 0.09)

2.7E−01

0.01

13

− 0.12( − 0.18, − 0.07)

7.5E−06*

− 0.10 (− 0.17, − 0.03)

7.1E−03

− 0.13( − 0.20, − 0.05)

1.9E−02

0.01

15

− 0.13 (− 0.18, − 0.08)

7.1E−07*

− 0.14 (− 0.21, − 0.07)

4.2E−05

− 0.14 (− 0.20, − 0.08)

6.7E−03

0.01

15

− 0.02 (− 0.06, 0.02)

4.1E−01

0.00 (− 0.05, 0.06)

9.0E−01

0.01 (− 0.05, 0.08)

7.3E−01

0.02

16

0.02 (− 0.02, 0.06)

3.5E−01

0.01 (− 0.04, 0.06)

6.6E−01

0.02 (− 0.04, 0.07)

6.1E−01

0.01

14

0.03 (− 0.02, 0.08)

2.2E−01

0.01 (− 0.04, 0.07)

6.4E−01

0.01 (− 0.04, 0.07)

6.6E−01

− 0.15 (− 0.27, − 0.03)

7.4E−02

− 0.05(− 0.15, 0.05)

3.6E−01

0.05 (− 0.06, 0.17)

4.1E−01

0.02 (− 0.10, 0.13)

8.0E−01

I2 = 86

SNPs = 7
Hgb (172,925)

4.6E−02

I2 = 84

SNPs = 10
Hct (173,039)

− 0.17 (− 0.29, − 0.05)

I2 = 87

SNPS = 8
RDW(171,529)

4.6E−01

I2 = 89

SNPs = 6
MCHC (172,851)

− 0.04 (− 0.15, 0.06)

I2 = 89

SNPs = 6
MCV(172,433)

2.8E−02

I2 = 87

SNPs = 9
MCH (172,332)

0.12 (0.01, 0.23)
I2 = 87

SNPs = 8

0.02

17

0.04 (0.00, 0.08)

8.3E−02

0.04 (− 0.01, 0.10)

1.0E−01

0.04 (− 0.02, 0.10)

2.6E−01

0.01 (− 0.11, 0.12)

8.9E−01

I2 = 85

SNPs = 8

Table 1.  Estimates of the effect of genetically influenced longer telomere length on nine blood-cell traits.
β beta estimate, CI confidence interval, P P value; *indicates below Bonferroni threshold (P < 0.006); RBC
red blood cell, WBC white blood cell, ret reticulocyte, MCH mean corpuscular hemoglobin, MCV mean
cell volume, MCHC mean corpuscular hemoglobin concentration, RDW red cell distribution width, Hct
hematocrit, Hgb hemoglobin.

from the analysis. SNP-exposure and SNP-outcome associations were harmonized with the “harmonization_data”
function within the MR-Base “TwoSampleMR” package within R
 42,55. Harmonized SNP-exposure and SNPoutcome associations were combined with the IVW method (Fig. 1).
For all tests, RadialMR regression56 was run to detect SNP outliers. Outlier SNPs were removed. (A different
number of telomere length SNPs were used for the various blood traits due to outliers being removed and whether
a SNP or its “proxy” was available in the outcome dataset.) All instrumental variables included in this analysis
have Cochrane’s Q-statistic P-values indicating no evidence for heterogeneity between S NPs57 (heterogeneity
statistics are provided in Supplementary Tables 10–18).
The selected SNPs correspond to independent genomic regions and account for 1% to 2% of the variance
in leukocyte telomere length (R2), which corresponds to F-statistics between 14 and 17. F-statistics are used to
gauge whether the IVW results suffer from reduced statistical power to reject the null hypothesis. This could
happen if telomere-length instrument explained a limited proportion of the variance in leukocyte telomere
length. F-statistics > 10 are conventionally considered to be sutiable58,59. The F-statistics and R2 values used to
calculate them are presented in Table 1.
In addition, I2 statistics, which are useful for assessing potential attenuation bias in one of the sensitivity estimators (the MR-Egger regression) are provided (also in Table 1). I2 statistics < 90% can indicate dilution in the
MR-Egger estimate, which can mean that the results from the MR-Egger intercept test (see below) are potentially
inaccurate. Simulation extrapolation (SIMEX), a correction procedure that adjusts the MR-Egger estimate for
potential regression dilution to the null, is recommended for I2 statistics < 90%60. The SIMEX results are reported
in Supplementary Tables 10–19.

Sensitivity analyses. The IVW estimator can be biased if any of the instrumental SNPs violate the MR
assumption about the genetic instrument not having a direct effect on the outcome independent of the e xposure61.
To assess possible violations to MR assumption (3), three sensitivity estimators—MR-Egger regression, weighted
median, and weighted mode methods—were run and their results compared with those of the IVW. The sensitivity estimators make different assumptions about the underlying nature of pleiotropy. Thus, if the directions
and magnitudes of their effects comport with those of the IVW, this is a qualitative screen against pleiotropy
(likewise, heterogeneity in their effects suggests pleiotropy)62. Comparing the IVW and sensitivity estimators is
a form of triangulation and knowledge synthesis—i.e., the judgement process for whether the results are consistent with causality is like what investigators do when they perform a systematic review of studies with different
methods, strenghts, and limitations.
In-depth explanations of the MR estimators and their assumptions have been covered e lsewhere61,63,64. The
results for the IVW and sensitivity estimators are reported in Table 1, except for the results of the MR-Egger
intercept tests. MR-Egger regression provides both an effect estimate and a test for directional pleiotropy (the
MR-Egger intercept test). The MR-Egger intercept test for pleiotropy is interpretted differently than the estimators providing tests for associations between telomere length and the blood-cell traits. When the MR-Egger
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intercept does not differ from zero (P > 0.05), this is evidence against pleiotropy. The MR-Egger intercept results
are reported in Supplementary Tables 10–18.

Number of tests. In total, nine MR tests were run (detailed characteristics for the individual SNPs used
in each model are provided in SupplementaryTables 1–9). Though it is over conservative due to the correlation
between blood traits, to account for multiple testing across analyses, a Bonferroni correction was used to establish a P-value threshold for strong evidence (P < 0.006) (false-positive rate = 0.05/9 outcomes).
Statistical software. SIMEX corrections were perfomed in Stata SE/16.065. All other described analyses
were performed in R version 3.5.2 with the “TwoSampleMR” package42.

Data availability

All data sources used for SNP-exposure and SNP-outcome associations are publicly available. The summary
data for the telomere length instruments are available in Haycock et al.20. The nine hematological outcome GWA
studies used for these analyses are accessible within MR-Base: https://www.mrbase.org/42.
Received: 2 April 2020; Accepted: 8 June 2020
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